The Zhitong Finance App learned that Goldman Sachs believes that the potential of the global diet pills market will continue to grow. Goldman Sachs analysts led by Chris Shibutani said that the diet drug market currently dominated by Novo Nordisk (NVO.US) and LLY.US (LLY.US) may reach 130 billion US dollars by 2030. Previously, the bank's forecast scale was 100 billion US dollars.
Currently, more and more drug developers are competing to tap the potential of the diet medicine market. At the same time, established leaders are also continuously expanding their share. The increase in industry size predictions further highlights the rapid development trend of the diet medicine market. Goldman Sachs listed some recent developments, including the approval of Eli Lilly's pharmaceutical product Zepbound, a huge increase in sales of Novo Nordisk's hit product Wegovy, and production investments that the two pharmaceutical giants are continuously pioneering.
The analysts wrote in a note on Thursday: “This update reflects our assessment of the impact of certain events that have occurred in several key areas since we last published our estimates, and these events have had a significant impact on our forecasting assumptions.”
Analysts also raised their forecast for the number of American adults taking diet pills for a long time from 15 million to 19 million, a figure that does not include people with type 2 diabetes.
Over the past year, Wall Street's enthusiasm for investing in the weight loss sector has also driven Lilly and Novo Nordisk's performance to new highs. The investment boom has solidified Eli Lilly's position as the world's largest healthcare company by market capitalization, and helped Danish pharmaceutical company Novo Nordisk become Europe's largest listed company by market capitalization.
Goldman Sachs still believes that by 2030, Eli Lilly and Novo Nordisk will maintain a market-leading position and account for around 80% of the global market share. However, they also pointed out that in terms of market share, Lilly is probably slightly superior to Pinot Noir and Nord.